The potential of miR-499 plasmatic level as a biomarker of obstructive sleep apnea syndrome

Biomark Med. 2021 Aug;15(12):1011-1019. doi: 10.2217/bmm-2020-0826. Epub 2021 Jul 22.

Abstract

Background: Obstructive sleep apnea syndrome (OSAS) is one of the most common sleep-related breathing disorders. The aim of this study was to improve diagnostics in OSAS using blood circulating biomarkers. We consider the potential of cardiac-specific miRNAs in the diagnosis and risk assessment of cardiovascular complications. Materials & methods: Plasmatic levels of miR-1-3p, miR-133a-3p and miR-499a-5p were measured by reverse transcription-PCR and compared with the clinical status of OSAS patients and controls. Results: The level of miR-499 was higher (p = 0.0343) in OSAS patients (mean expression: 0.00561) compared with the controls (mean expression: 0.00003), using the multivariate logistic regression. Conclusion: The role of miR-499 in gene expression regulation during hypoxia and our findings indicate that miR-499 could be a new diagnostic biomarker for OSAS.

Keywords: biomarker; cardiovascular disease; miR1; miR133a; miR499; miRNA; sleep apnea syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood*
  • Female
  • Gene Expression Regulation
  • Humans
  • Logistic Models
  • Male
  • MicroRNAs / genetics*
  • Middle Aged
  • Multivariate Analysis
  • ROC Curve
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sleep Apnea, Obstructive / blood*
  • Sleep Apnea, Obstructive / diagnosis
  • Sleep Apnea, Obstructive / genetics

Substances

  • Biomarkers
  • MIRN499 microRNA, human
  • MicroRNAs